MCM
TGTX icon

Moore Capital Management’s TG Therapeutics TGTX Stock Holding History

Moore Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-97,635
Closed -$816K – 542
2023
Q3 		$816K Buy
+97,635
New +$1.36M 0.02% 311

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Moore Capital Management's TGTX Position: Q4 2023 in Review

Moore Capital Management sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 97,635 shares — an estimated $816K sold.

Moore Capital Management first reported a position in TGTX in Q3 2023 and held it in 1 quarter. The position peaked at $816K in Q3 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • Moore Capital Management reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 97,635 TG Therapeutics shares in Q4 2023, an estimated $816K.
  • Moore Capital Management first reported a position in TG Therapeutics in Q3 2023 and held it in 1 quarter.
  • Moore Capital Management's TG Therapeutics position peaked at $816K in Q3 2023.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.